Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

55.77 -0.13 (-0.23%)

Streaming Delayed Price Updated: 9:37 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

January 02, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

December 19, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

December 18, 2025

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

December 11, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend Increase

December 10, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

December 08, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 04, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

December 03, 2025

From Bristol Myers Squibb

Via Business Wire

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

Via Investor Brand Network

Topics Government

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

From BioMedWire

Via GlobeNewswire

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

December 01, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

November 26, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

November 24, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Host Hematology-Focused Investor Event

November 24, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

November 18, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

November 17, 2025

From Bristol Myers Squibb

Via Business Wire

Update on Phase 3 Librexia ACS Trial

November 14, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

November 05, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025

November 03, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

November 03, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

October 30, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

October 27, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

October 25, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

October 13, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

October 10, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

October 10, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

October 01, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

September 25, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

September 23, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

September 19, 2025

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.